Read Beaufort Securities's note on ANGLO PACIFIC GROUP PLC (APF), out this morning on Research. It's completely free to view. "Anglo Pacific's performance in Q1 2016 was in line with expectations. The company expects the majority of royalty income in H2 2016, as in the previous year. The Narrabri and Kestrel coal mines in Australia are progressing well, with production expected at Kestrel and a full year of income for the Narrabri royalty. Anglo Pacific also received first receipts from its Four Mile uranium royalty during the period. Meanwhile, the company witnessed positive developments at Berkeley, with the market value of royalty around US$10m higher than the carrying value in its balance sheet. We expect Anglo Pacific to deliver as per the expectations in the year, well supported by recovery in coking coal prices. Therefore..."
Read Beaufort Securities's note on ANGLE PLC (AGL), out this morning, by visiting Research Tree: "Ground-breaking potential in detection of cancer, which is now funded to comprehensively demonstrate Parsotix's utility! Parsortix offers the same clinically relevant information from a patient's blood test, irrespective of its location in the body, that otherwise can only be obtained from an invasive metastatic biopsy. Though extensive development and clinical trials will be required across a wide range of indications before such tests to achieve standard international acceptance by medical and insurance providers, much earlier and elementary testing for cancer detection looks set to become a reality. Significantly in this respect, ANGLE differentiates itself from other medtech companies claiming similar abilities. In recent months, the medical world has become aware of a number of new, innovative, but early stage, non-invasive tests (be they derived from blood, saliva, sweat, antibodies etc.) that are apparently also capable of elementary and accurate detection of cancer. The fact remains, however, that detection in the form of a simple 'most probably yes' or 'most probably no' is, in fact, of only limited use unless the test is also capable of capturing or harvesting the same cancer cells for laboratory analysis. Without this, doctors will remain unable to ascertain key information, including identifying the cancer itself along with the extent to which it is aggressive or benign and therefore how to treat it. As such, ANGLE is the only such detection technology that is capable of offering such analysis and so, in Beaufort's opinion, is much more likely to become the globally recommended standard for hospitals and associated medical institutes. Yesterday's news drove this point home. Not only was the Group able to secure major new funding from professional investors in order to progress clinical studies, but it also confirmed a UK contract which allows for routine clinical and research use, itself a key part of the Group's strategy for commercialisation. The funds now available are expected to be sufficient to cover the next 2 years of planned clinical studies, which will be bolstered further by rising research sales. Assuming all goes to plan, ongoing studies of ovarian cancer should have sufficiently concluded to permit first commercial sales to EU hospitals during 1H'2017. Beyond this, FDA authorisation for metastatic breast cancer is expected to be secured through substantive studies defined by three major US-based centres. Successful conclusion here, potentially offers scope for initial North American commercial sales for MBC later in 2017. Further indications, including ovarian and prostate will seek a similar route with the FDA..."
Read Edison's note on Cenkos Securities, published this morning on Research Tree. It's completely free to view. "Cenkos (CNKS) is a specialist institutional stockbroker with a consistent track record of profitability since its formation. Its entrepreneurial approach has helped attract an expanding client list and win mandates for substantial transactions, including the fund raise of over £1bn for BCA last year. The level of profit is subject to market fluctuations but the current valuation appears to reflect cautious assumptions given the group’s historical performance and attractive yield..."
Northland Capital Partners's note on Savannah Resources (SAV), out this morning on Research Tree. "Savannah Resources has completed gravity surveys over three areas; VTEM 13 (Block4), Ghayth (Block4) and Sarami West (Block 5) that contains 12 VTEM and EM anomalies. These areas were previously drill tested in 2015 defining alteration systems that confirmed the potential for VMS mineralisation the results of the gravity surveys will further refine drill targets. The two stage 2,930m drill programme continues as planned at the Maqail South and Mahab 4 prospects (Block 5) and Dog’s Bone and Bayda prospects (Block4)..."
Northland Capital Partners's note on Mariana is out on Research Tree this morning. "The southern area of Hot Maden (Figure 1) is now a significant exploration target for Mariana Resources and its joint venture partner Lidya. The Company has defined multiple narrow ultra-high-grade quartz sulphide veins similar in style to what was previously mined in the 1920’s. The southern area now represents another level of upside beyond the resource expansion drilling located in closer proximity to the existing resource base. Drilling continues both on the southern area and in and around the existing mineral resource area..."
Northland Capital Partners published a note on Immupharma this morning, it's out on Research Tree: "Alto’s investment further corroborates our view that ImmuPharma represents a good investment opportunity. The group’s lead drug, a potential treatment for Lupus, currently in a Phase 3 clinical trial, is expected to deliver a pivotal read-out by the end of 2017..."
Read Stockdale Securities's note on ADVANCED ONCOTHERAPY PLC (AVO), out this morning on Research Tree. "We view today’s news of a financing agreement between Advanced Oncotherapy (AVO) and Metric Capital positively. The agreement will enable AVO and its partners to complete the London Proton Therapy Centre in Harley Street, the site of the first commercial LIGHT system. We shall publish an updated research report when the 2015 final results are released next month. Ahead of this and on the back of today’s significant progress we are happy to..."
Read Panmure Gordon & Co's note on Savannah Petroleum, out this morning on Research Tree "Following an eventful year, Savannah reported a loss of US$7.9m for FY15 and had cash and net cash at 31 December of US$7.8m. The company expects to update on the potential reverse take-over transaction over the course of the next month. Savannah anticipates a return to operational activity in 2H16 including the commencement of 3D seismic acquisition focusing on the R3 area of its extensive Nigerien acreage position in the proven Agadem Rift Basin. The company expects to commence drilling activity in 1H17 targeting 10+ explo..."
Read Arden Partners's note on SCAPA GROUP PLC (SCPA), out this morning on Research Tree: "Finals reflected good underlying progress across both the Healthcare and Industrial divisions as well as a full year contribution from First Water, which was acquired in February 2015. Revenues increased 4.5% to £246.7m, (+4.1% constant FX) and with the trading margin improving from 7.9% to 8.6%, trading profits grew 14.5% to £21.3m (+14.5% constant FX). Adjusted PBT (excluding pension costs and exceptionals) was up 15.1% to £20.6m and adjusted EPS grew 16.5% to 10.6p, helped by a slight reduction in the tax rate..."
Read Edison's note on Rockhopper Exploration, out this morning on Research Tree: "The release of the independent audit of Rockhopper’s (RKH’s) assets confirms that contingent 2C resources at Sea Lion exceed 500mmboe. This should give further comfort to investors on the value of the project, which should continue to benefit from the deflating cost environment. Elsewhere, due to issues during the redrilling of Isobel, the data available to the company and auditors were only enough to substantiate 2C volumes of 20mmboe at this time. However, the company remains very confident (with appraisal) that the..."